@Article{,
AUTHOR = {Joshua Winograd, John Lama, Alia Codelia-Anjum, Naeem Bhojani, Dean S. Elterman, Kevin C. Zorn, Eric Margolis, Jamin Brahmbhatt, Ricardo Gonzalez, Bilal Chughtai},
TITLE = {Measuring the efficacy of Serenoa repens (USPlus) extract with mobile uroflowmetry},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {31},
YEAR = {2024},
NUMBER = {6},
PAGES = {12053--12059},
URL = {http://www.techscience.com/CJU/v31n6/59554},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Benign prostatic hyperplasia (BPH) is
a prevalent condition affecting a significant portion of
the male population, leading to secondary lower urinary
tract symptoms (LUTS). Alternative therapies such as
phytotherapy using Lipidosterolic extract of Serenoa
repens (LSESR USPlus) are commonly used. However,
the efficacy of LSESr remains controversial due to
conflicting data. We sought to determine the effect of a
standardized USP-verified Saw Palmetto extract on male
LUTS secondary to BPH.<br/>
<b>Materials and methods:</b> In this prospective single
arm trial, we investigated the efficacy of a standardized USP-verified Saw Palmetto extract in treating male
LUTS secondary to BPH. We utilized the ProudP
mobile application for home uroflowmetry and symptom
assessment.<br/>
<b>Results:</b> Results from 46 patients using 320 mg
daily of USP-verified Saw Palmetto extract revealed
significant improvements in IPSS and QoL scores at
12 weeks compared to baseline, particularly in patients
with moderate symptoms. Uroflowmetry parameters also
improved with increased flow rates, primarily in patients
with mild symptoms.<br/>
<b>Conclusion:</b> Our findings support the efficacy of USP
verified Saw Palmetto extract in alleviating LUTS in
men with BPH. Further studies are warranted in larger,
diverse cohorts over longer follow up periods.},
DOI = {}
}